Trial Profile
Randomized, Open, Multicenter Study to Evaluate the Renal Function of HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Rosuvastatin/telmisartan (Primary) ; Telmisartan
- Indications Hyperlipidaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Yuhan
- 06 Dec 2022 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified December 2020).
- 11 Dec 2020 Planned End Date changed from 1 Aug 2021 to 1 Dec 2021.
- 11 Dec 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Dec 2021.